Erudio Healtherudio.com
Sponsor
Eli Lilly trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Eli Lilly: CYCLONE 3. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 32 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Eli Lilly and Company; Loxo Oncology, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| CYCLONE 3 NCT05288166 · Eli Lilly and Company | high-risk metastatic hormone-sensitive prostate cancer | Phase 3 | 218 | 14 | Standard | Nov 17, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| monarchE NCT03155997 · Eli Lilly and Company DeepView → | HR+, HER2-negative, node-positive, high-risk early breast cancer | Phase 3 | Deep | View | |||
| EMBER-3 NCT04975308 · Eli Lilly and Company DeepView → | ER+, HER2- advanced breast cancer | Phase 3 | Deep | View | |||
| postMONARCH NCT05169567 · Eli Lilly and Company DeepView → | HR+, HER2- advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| LIBRETTO-432 NCT04819100 · Eli Lilly and Company DeepView → | stage IB-IIIA RET fusion-positive NSCLC | Phase 3 | Deep | View | |||
| LIBRETTO-001 NCT03157128 · Eli Lilly and Company DeepView → | RET-activated advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| MONARCH 2 NCT02107703 · Eli Lilly and Company DeepView → | hormone receptor-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| BRUIN CLL-313 NCT05023980 · Loxo Oncology, Inc. DeepView → | untreated chronic lymphocytic leukemia/small lymphocytic lymphoma | Phase 3 | Deep | View | |||
| LOXO-RAS-20001 NCT04956640 · Eli Lilly and Company DeepView → | KRAS G12C-mutant advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| EMBER-4 NCT05514054 · Eli Lilly and Company DeepView → | ER+, HER2- early breast cancer | Phase 3 | Deep | View | |||
| REACH-2 NCT02435433 · Eli Lilly and Company DeepView → | second-line advanced hepatocellular carcinoma with elevated alpha-fetoprotein | Phase 3 | Deep | View | |||
| NEXUS-01 NCT06465069 · Eli Lilly and Company DeepView → | advanced urothelial carcinoma or other solid tumors | Phase 1 | Deep | View | |||
| LIBRETTO-531 NCT04211337 · Loxo Oncology, Inc. DeepView → | kinase inhibitor-naïve advanced RET-mutant medullary thyroid cancer | Phase 3 | Deep | View | |||
| FORAGER-2 NCT07218380 · Eli Lilly and Company DeepView → | Not given | Phase 3 | Deep | View | |||
| CYCLONE 2 NCT03706365 · Eli Lilly and Company DeepView → | metastatic castration-resistant prostate cancer | Phase 2/Phase 3 | Deep | View | |||
| EMBER NCT04188548 · Eli Lilly and Company DeepView → | ER+ advanced breast cancer and endometrial cancer | Phase 1 | Deep | View | |||
| FORAGER-1 NCT05614739 · Eli Lilly and Company DeepView → | advanced solid tumors with FGFR3 alterations | Phase 1 | Deep | View | |||
| BRUIN NCT03740529 · Loxo Oncology, Inc. DeepView → | previously treated CLL/SLL or non-Hodgkin lymphoma | Phase 1/Phase 2 | Deep | View | |||
| BRUIN MCL-321 NCT04662255 · Loxo Oncology, Inc. StandardView → | previously treated, BTK inhibitor-naïve mantle cell lymphoma | Phase 3 | Standard | View | |||
| MONARCH 1 NCT02102490 · Eli Lilly and Company StandardView → | previously treated hormone receptor-positive, HER2-negative metastatic breast cancer | Phase 2 | Standard | View | |||
| neoMONARCH NCT02441946 · Eli Lilly and Company StandardView → | postmenopausal HR+/HER2- early-stage breast cancer | Phase 2 | Standard | View | |||
| SUNRAY-01 NCT06119581 · Eli Lilly and Company StandardView → | first-line advanced KRAS G12C-mutant non-small cell lung cancer | Phase 3 | Standard | View | |||
| SUNRAY-02 NCT06890598 · Eli Lilly and Company FocusedView → | stage II-III KRAS G12C-mutant non-small cell lung cancer | Phase 3 | Focused | View | |||
| FRAmework-01 NCT07213804 · Eli Lilly and Company FocusedView → | platinum-resistant and platinum-sensitive ovarian cancer | Phase 3 | Focused | View | |||
| BRUIN CLL-321 NCT04666038 · Loxo Oncology, Inc. FocusedView → | BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma | Phase 3 | Focused | View | |||
| LIBRETTO-431 NCT04194944 · Eli Lilly and Company FocusedView → | first-line RET fusion-positive advanced non-small cell lung cancer | Phase 3 | Focused | View | |||
| RELAY NCT02411448 · Eli Lilly and Company FocusedView → | untreated EGFR-mutated metastatic NSCLC | Phase 3 | Focused | View | |||
| LIBRETTO-121 NCT03899792 · Eli Lilly and Company FocusedView → | pediatric advanced RET-altered solid or primary CNS tumors | Phase 1/Phase 2 | Focused | View | |||
| CYCLONE 1 NCT04408924 · Eli Lilly and Company FocusedView → | heavily treated metastatic castration-resistant prostate cancer | Phase 2 | Focused | View | |||
| MOONRAY-01 NCT06586515 · Eli Lilly and Company FocusedView → | KRAS G12D-mutant solid tumors | Phase 1 | Focused | View | |||
| MONARCH 3 NCT02246621 · Eli Lilly and Company FocusedView → | first-line HR+/HER2- advanced breast cancer | Phase 3 | Focused | View | |||
| SEQUOIA NCT02923921 · Eli Lilly and Company FocusedView → | second-line metastatic pancreatic cancer | Phase 3 | Focused | View | |||
| BRUIN CLL-322 NCT04965493 · Loxo Oncology, Inc. FocusedView → | previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma | Phase 3 | Focused | View | |||